IgniteData raises $11M Series A to scale Archer globally & sites.

IgniteData has completed an oversubscribed $11M Series A round that the company says will accelerate global expansion of its clinical-data automation platform, Archer. The financing, announced this week, brings new strategic backers and fresh resources to push generative-AI mapping and site integration across sponsors and research hospitals.

The round was led by FCA Venture Partners, with the Labcorp Venture Fund and Epsilon anchoring the final close. Existing investors including SpringTide and Oncology Ventures participated and increased allocations. Several experienced healthcare technology leaders — Thomas Tarnowski, Marc Vangerven and Andy Cooper — also invested personally, signalling both sector expertise and practical endorsement.

According to Zach Taft, CEO of IgniteData, the capital will fund three priorities: scaling the company’s network of research sites, speeding product development for Archer, and deepening work on generative-AI driven data extraction. Taft described the round as a step to reduce clinical-site burden and compress trial timelines by enabling near real-time, validated transfers from EHRs into EDCs and sponsor data warehouses.

Digital tools that streamline clinical data flows and automate source-to-capture mapping are part of a broader shift in trial operations: sponsors, contract research organisations and study sites are increasingly adopting AI-assisted data pipelines to cut cycle time and lower per-patient costs. Investors have shown steady appetite for healthtech and life-sciences data platforms, with Series A financings commonly ranging from single-digit to mid-double-digit millions when technology and regulatory-readiness align.

IgniteData’s approach combines deterministic mapping, model-assisted extraction and role-based security to deliver auditable transfers. That architecture is important for regulators and for European deployments where GDPR compliance and local data residency are essential. The firm said the new funding will support expansions in Europe — including adapting workflows for regional EHR systems and privacy regimes — as well as growth in North America and other markets.

Industry backers framed the investment as strategic. Labcorp’s new-ventures lead highlighted the potential to lower site workload and improve dataset quality, while Epsilon’s partners cited the company’s blend of clinical domain knowledge and scalable engineering. Returning investors emphasised execution: early believers increased exposure after seeing product traction and pilot outcomes at academic research centres and pharma sponsors.

Looking ahead, the round positions IgniteData to pursue deeper integrations with CROs and enterprise sponsors, accelerate validation of AI mapping for regulated contexts, and expand commercial deployment of Archer.